Two independent Zika vaccine research threads emphasized CD8+ T cells as a key protective arm. Researchers at the La Jolla Institute for Immunology reported that an engineered Zika vaccine approach—using envelope fusion-loop mutations designed to avoid generating cross-reactive neutralizing antibodies—protected mice via CD8+ T cells in work published in Nature Microbiology. Complementing the vaccine mechanism focus, separate reporting described T cell-driven vaccine constructs engineered around fusion-loop mutations, again pointing to protection through cellular immunity rather than conventional antibody neutralization. Together, the studies refine the design logic for Zika vaccination by prioritizing T cell quality—particularly relevant given historical concerns about antibody interactions with related mosquito-borne viruses.